Physician profile
Paula J Rust
NPI 1194921254
$1,353.17
in general payments reported to CMS, 2019-2025
30 companies · $20.78 in 2025
The $20.78 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $90.39 · 2021: $481 · 2022: $213 · 2023: $171 · 2024: $196 · 2025: $20.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $358.63 | 2019-2022 | |
| Hologic Sales and Service, LLC | $144.87 | 2019-2024 | Novasure, Fluent Fluid Management System, Myosure Tissue Removal Device |
| Evofem Biosciences, INC. | $77.72 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $75.96 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.17 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $55.58 | 2023 | |
| Radius Health, INC. | $51.84 | 2024-2025 | Tymlos |
| Scynexis, INC. | $50.64 | 2021-2022 | |
| Amgen INC. | $43.61 | 2019 | |
| Channel Medsystems, INC. | $34.20 | 2023 | |
| Mission Pharmacal Company | $31.46 | 2019 | |
| Coopersurgical, INC. | $28.88 | 2020-2021 | |
| Astellas Pharma US INC | $28.02 | 2019-2024 | Veozah |
| Sumitomo Pharma America, INC. | $28.00 | 2024 | Myfembree |
| Amag Pharmaceuticals, INC. | $25.08 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $24.49 | 2022 | |
| Exeltis, USA INC. | $21.65 | 2021 | |
| Duchesnay USA Incorporated | $21.13 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.01 | 2023 | Linzess |
| Merck Sharp & Dohme LLC | $17.69 | 2022 | |
| Lupin INC. | $17.53 | 2021 | |
| Agile Therapeutics, INC. | $15.59 | 2021 | |
| Medtronic, INC. | $15.54 | 2021 | |
| Minerva Surgical, INC | $15.51 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $15.30 | 2020 | |
| Therapeuticsmd, INC. | $13.84 | 2021 | |
| Shield Therapeutics INC | $13.08 | 2024 | |
| Coloplast Corp | $12.42 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.92 | 2021 | |
| Pfizer INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Rust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.